LTRN LANTERN PHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, LANTERN PHARMA INC reported revenue of n/a, net income of −$7.07M and diluted EPS of −$0.57; for the fiscal year ended December 2025 revenue was n/a.
LTRN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$18.0M, net income −$17.1M (margin n/a), EPS −$1.57
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$22.2M, net income −$20.8M (margin n/a), EPS −$1.93
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$17.9M, net income −$16.0M (margin n/a), EPS −$1.47
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$14.4M, net income −$14.3M (margin n/a), EPS −$1.31
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$12.6M, net income −$12.4M (margin n/a), EPS −$1.13
LTRN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$7.07M, EPS −$0.57
- Quarter ended Mar 31, 2026: revenue n/a, net income −$3.33M, EPS −$0.30
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$4.07M, EPS −$0.36
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.18M, EPS −$0.39
- Quarter ended Jun 30, 2025: revenue n/a, net income −$4.33M, EPS −$0.40
- Quarter ended Mar 31, 2025: revenue n/a, net income −$4.54M, EPS −$0.42
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$5.88M, EPS −$0.54
- Quarter ended Sep 30, 2024: revenue n/a, net income −$4.51M, EPS −$0.42
- Quarter ended Jun 30, 2024: revenue n/a, net income −$4.96M, EPS −$0.46
- Quarter ended Mar 31, 2024: revenue n/a, net income −$5.44M, EPS −$0.51
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$4.19M, EPS −$0.38
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.16M, EPS −$0.29
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.75M, EPS −$0.44
- Quarter ended Mar 31, 2023: revenue n/a, net income −$3.87M, EPS −$0.36
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$3.38M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$2.26M, EPS −$0.21
- Quarter ended Jun 30, 2022: revenue n/a, net income −$4.49M, EPS −$0.41
- Quarter ended Mar 31, 2022: revenue n/a, net income −$4.12M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$3.54M, EPS −$0.32
- Quarter ended Sep 30, 2021: revenue n/a, net income −$4.05M, EPS −$0.36
LTRN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$15.7M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$17.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$14.3M, share buybacks $500K
- Fiscal year ended Dec 2022: operating cash flow −$12.8M, share buybacks $2.48M
- Fiscal year ended Dec 2021: operating cash flow −$10.6M, share buybacks $940K
LTRN balance sheet
- Jun 30, 2026: cash $6.66M, total assets $8.60M, total liabilities $11.8M, shareholders' equity −$3.22M
- Mar 31, 2026: cash $4.92M, total assets $7.22M, total liabilities $3.78M, shareholders' equity $3.45M
- Dec 31, 2025: cash $4.42M, total assets $11.0M, total liabilities $4.50M, shareholders' equity $6.53M
- Sep 30, 2025: cash $8.39M, total assets $13.6M, total liabilities $4.04M, shareholders' equity $9.59M
- Jun 30, 2025: cash $6.06M, total assets $17.4M, total liabilities $4.90M, shareholders' equity $12.5M
- Mar 31, 2025: cash $6.38M, total assets $21.1M, total liabilities $4.32M, shareholders' equity $16.8M
- Dec 31, 2024: cash $7.51M, total assets $25.6M, total liabilities $4.38M, shareholders' equity $21.2M
- Sep 30, 2024: cash $8.10M, total assets $30.3M, total liabilities $3.70M, shareholders' equity $26.6M
Is LTRN profitable?
No. LANTERN PHARMA INC lost $18.7M over the last four quarters.
What is LTRN's EPS?
Diluted earnings per share over the last four quarters were −$1.62; −$0.57 in the latest quarter.